MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX ®, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with ...
Denver, CO (May 11, 2013): Use of TYRX, Inc.'s AIGISRx® Antibacterial Envelope reduced major infection rates by more than 90% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) ...
In patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to similar high-risk cohorts, use of TYRX, Inc.'s AIGISRx® Antibacterial Envelope reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results